Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05489328 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 394
- Enrollment target
NCT05489328 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 394 participants.
The verdict
NCT05489328, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 394 participants
- Enrollment target
Study Summary
The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.
Interventions
- OTHER Candidate-1
- OTHER Candidate-2
- OTHER Candidate-3
- OTHER Candidate-4
- OTHER Candidate-5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05489328
The ClinicalTrials.gov registry entry for NCT05489328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Candidate-1 is the first listed.
NCT05489328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05489328 about?
NCT05489328 is a clinical study titled "Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age". The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.
What is the current status of trial NCT05489328?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 394 participants. The study started on 2022-08-15. Estimated completion is 2022-10-07.
What interventions are being tested in trial NCT05489328?
The interventions under investigation include: Candidate-1 (OTHER), Candidate-2 (OTHER), Candidate-3 (OTHER), Candidate-4 (OTHER), Candidate-5 (OTHER).
Who is sponsoring clinical trial NCT05489328?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.